US Pharma MarketingThe post BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM appeared first on Clinical Trials Arena.
BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM
BMS has reported positive top-line results from the Phase II QUINTESSENTIAL trial of BMS-986393 in adults with quadruple-class exposed r/r MM. The multi-centre, single-arm, open-label study achieved its primary endpoint. The study is evaluating the efficacy and safety of arlo-cel in patients who have previously received CAR T-cell therapies. Credit: PanuShot / Shutterstock.com. Bristol Myers Squibb (BMS) has reported positive top-line results from the registrational Phase II QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; BMS-986393) in adults with quadruple-class exposed relapsed and refractory multiple myeloma (r/r MM). Arlo-cel is an autologous G protein-coupled receptor class C group 5 member D (GPRC5D)-directed…
BMS has reported positive top-line results from the Phase II QUINTESSENTIAL trial of BMS-986393 in adults with quadruple-class exposed r/r MM.
Source: Clinical Trials Arena